HOME >> BIOLOGY >> NEWS
Pharmaceutical 'smart bomb' targets cancer cells

NEW BRUNSWICK/PISCATAWAY, N.J. Rutgers pharmaceutical chemist Longqin Hu and his colleagues have developed a new series of compounds for drugs that have the potential to attack cancer like a high-tech "smart bomb." This high-powered combination of a novel cell-killing agent and a precision targeting technology proved to be as much as 100 times more potent than a comparable drug currently in clinical trials.

"We are testing this combination and it looks like a winner," said Hu, an assistant professor at the Ernest Mario School of Pharmacy at Rutgers, The State University of New Jersey.

The delivery of the compound is accomplished with a prodrug an inert chemical derivative of a drug that can be activated once it reaches its destination inside a patient's body. Prodrugs can transport highly potent medicines such as Hu's cytotoxins (cell-killers), without impacting other body tissues along the way. Hu's research employs a new and improved prodrug package developed by collaborators in England.

This dramatic step in the march toward a cancer cure will be featured twice during the 226th American Chemical Society (ACS) national meeting in New York. Hu is presenting a paper on Monday, Sept. 8 at 3:45 p.m. in the Javits Convention Center, room 1E02. In addition, Hu and his colleagues are exhibiting at a poster session on Wednesday, Sept. 10 in the Hilton New York, Americas Hall 1 from 6 p.m. to 8 p.m.

Traditional anticancer drugs use accelerated cell growth as their trigger, which can produce collateral damage in rapidly replicating normal cells. "That is how you wind up with the negative side effects you see in chemotherapy patients, such as hair loss, nausea and reduced immunities," said Hu.

Instead of hitting all cells that grow fast, the newly reformulated prodrugs use a protein or enzyme as the activating trigger, guaranteeing a direct hit on cancerous cells. Nitroreductase an enzyme not normally found in the body, not
'"/>

Contact: Joseph Blumberg
blumberg@ur.rutgers.edu
732-932-7084 Ext. 652
Rutgers, the State University of New Jersey
31-Dec-2000


Page: 1 2

Related biology news :

1. Warren Pharmaceuticals publishes results of preclinical evaluation
2. Cyclis Pharmaceuticals reports studies defining new mechanism for potential cancer therapies
3. Final results of the two Zevalin pivotal trials in radioimmunotherapy for B cell Non-Hodgkins Lymphoma announced by IDEC Pharmaceuticals
4. Pharmaceutical and personal care products: What happens when they enter the environment - an emerging concern
5. Researchers, Regulators, Industry, Consumer Advocates Gather to Discuss Critical Issues Facing the Pharmaceutical Industry
6. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
7. Idun Pharmaceuticals Identifies Cell Type And Molecular Pathway Involved In TransplantationRelated Liver Damage
8. Cubist Pharmaceuticals Describes New VITA™ Technology For Enabling Genomics For Drug Discovery
9. Vertex Pharmaceuticals/Yale Research Team Uses Gene Knockout Mice To Establish Role Of Caspase-9 In Neuronal Cell Death Pathway
10. Micro-Plants Yield Pharmaceutical New Wave
11. Scientists At The Scripps Research Institute And R.W. Johnson Pharmaceuticals Develop New Antibacterial Agents

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/6/2017)... March 6, 2017 Mintigo , ... today announced Predictive Sales Coach TM , its ... sales intelligence into Salesforce. This unique AI application ... sales organizations with deep knowledge of their customers ... intelligent engagement. Predictive Sales Coach extends Mintigo,s existing ...
(Date:3/2/2017)... March 2, 2017 Summary This ... understand Merck KGaA and its partnering interests and activities ... Description The Partnering Deals and Alliance since ... activity of one of the world,s leading life sciences ... upon purchase to ensure inclusion of the most up ...
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
Breaking Biology News(10 mins):
(Date:3/22/2017)...   iSpecimen ®, the marketplace for ... Service (DPS), a full-service anatomic pathology reference lab ... States , has joined a program offered by ... (DHIN) to make human biospecimens and associated data available ... announced in 2015 as a collaboration between iSpecimen and ...
(Date:3/22/2017)... March 22, 2017 /PRNewswire/ - FACIT announced a ... or "Propellon"), a start-up created by FACIT focused ... FACIT,s investment, combined with non-dilutive capital, achieves a ... seed funding enables Propellon to accelerate the nomination ... for financing and/or entering a strategic partnership for ...
(Date:3/22/2017)... (PRWEB) , ... March 21, 2017 , ... Premier executive ... & Life Science Search Firm by Hunt Scanlon Media. , Hunt Scanlon ... and the most widely referenced global news source in the human capital sector. , ...
(Date:3/22/2017)... ... March 21, 2017 , ... Benchworks CEO ... Executive Officer Forum on March 23-24 in San Diego. The event is a ... diagnostic industries. , Benchworks Vice President Christian Meyer will also participate in the ...
Breaking Biology Technology:
Cached News: